Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)
24 sept. 2020 14h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the...
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
29 janv. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
22 déc. 2017 08h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
09 déc. 2017 08h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05 déc. 2017 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally...
Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases
03 sept. 2014 05h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead
first-in-class inflammation/auto-immune assets, RP6503 and RP3128
in...